Moderator

The CADTH (independent advisory body Health Canada consulted with) has published its recommendations on Edaravone use in Canada based on their research and consultations with ALS patients, caregivers and other health professionals.

From ALS Canada

Were you among the 550 Canadians who participated in last summer’s survey about experience with edaravone? CADTH has released its reimbursement recommendation that was informed in part by your input. The report recommends that provinces and territories publicly fund edaravone based on certain criteria. As we move forward, we will continue to voice the need for timely, equitable and affordable access to ALS therapies

For questions related to access of the drug, we encourage you to consult a neurologist at your ALS clinic for the most up-to-date information.